K-ras mutations in the plasma of colorectal cancer patients

Laboratory Medicine

Volumn 41, Issue 3, 2010, Pages 156-158

  Shen, Yong Qi ^a   Ye, Yun Bin ^a   Zheng, Xiong Wei ^a   Li, Chao ^a   Chen, Qiang ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DNA;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; COLORECTAL CANCER; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PLASMA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS;

EID: 77951973116     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LMZ100VWSHJZPLVO     Document Type: Article

References (16)

1. Vogelstein BA, Kinzler KW. The multistep nature of cancer. Trends Genet. 1993;9:138-141.
2. Fearon ER, Vogelstein BA. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759-767.
3. Lievre A, Bachet JB, Boige V, et al. K-ras mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66:3992-3995.
4. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25:3230-3237. (Pubitemid 47325606)
5. Tejpar S, Peeters M, Humblet Y, et al. Relationship of efficacy with KRAS status (wild type versus mutant) in patients with irinotecan-refractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximiab (ql w): The EVEREST experience. J Clin Oncol. 2008;26:4001.
6. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Proc Am Soc Clin Oncol. 2007;25:185.
7. Van Cutsem E, Lang I, D'haens G, et al. K-RAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIR1 with or without cetuximab: The CRYTAL experience. J Clin Oncol. 2008;26:2.
8. Bokemeyer C, Bondarenko L, Hartmann JT, et al. KRAs status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol. 2008;26:4000.
9. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-1634.
10. Cserni G. The influence of nodal size on the staging of colorectal carcinomas. J Clin Pathol. 2002;55:386-390. (Pubitemid 34494180)
11. Minamoto T, Mai M, Ronai Z. K-ras mutation early detection in molecular diagnosis and risk and assessment of colorectal pancreas and lung cancers. Cancer Detect Prev. 2000;24:1-12. (Pubitemid 30152735)
12. Brink M, de Goeij AFPM, Weijenberg MP, et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands COHORT Study. Carcinogenesis. 2003;24:703-710. (Pubitemid 36592405)
13. Halatsch ME, Hirsch KI, Weinel RJ, et al. Differential activation of the c-K-ras-2 proto-oncogene in human colorectal carcinoma. Anti-cancer Res. 1998;18:2323-2325.
14. Slattery ML, Curtin K, Anderson K, et al. Associations between dietary intake and K-ras mutations in colon tumors: A population based study. Cancer Res. 2000;60:6935-6941. (Pubitemid 32059166)
15. Doolittle BR, Emannel J, Tuttle C, et al. Detection of the mutated K-ras biomarker in colorectal carcinoma. Exp Mol Pathol. 2001;70:289-301. (Pubitemid 32607202)
16. Lindforss U, Zetterquist H, Papadogiannakis N, et al. Persistence of K-ras mutation in plasma after colorectal tumor resection. Anticancer Res. 2005;25:657-662. (Pubitemid 40470078)